- Title
- Anti-Angiopoietin Therapy with Trebananib for Recurrent Ovarian Cancer (TRINOVA-1): A Randomised, Multicentre, Double-Blind, Placebo-Controlled Phase 3 Trial
- Creators
- Bradley J. Monk (Author) - Creighton UniversityA. Poveda (Author)I. Vergote (Author)F. Raspagliesi (Author)K. Fujiwara (Author)D. -S Bae (Author)A. Oaknin (Author)I. Ray-Coquard (Author)D. M. Provencher (Author)B. Y. Karlan (Author)C. Lhommé (Author)G. Richardson (Author)D. G. Rincón (Author)R. L. Coleman (Author)T. J. Herzog (Author)C. Marth (Author)A. Brize (Author)M. Fabbro (Author)A. Redondo (Author)A. Bamias (Author)M. Tassoudji (Author)L. Navale (Author)D. J. Warner (Author)A. M. Oza (Author)
- Additional links
- http://doi.org/10.1097/01.ogx.0000458794.60509.a8
- Publication Details
- Obstetrical and Gynecological Survey, Vol.69(11), pp.661-662
- Number of pages
- 661-662
- Identifiers
- 991005931592602656
- Academic Unit
- School of Medicine; Obstetrics & Gynecology; General Medicine
- Resource Type
- Journal article
Journal article
Anti-Angiopoietin Therapy with Trebananib for Recurrent Ovarian Cancer (TRINOVA-1): A Randomised, Multicentre, Double-Blind, Placebo-Controlled Phase 3 Trial
Obstetrical and Gynecological Survey, Vol.69(11), pp.661-662
11/2014
Metrics
3 Record Views